Wedgewood Investors Inc. PA lessened its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,921 shares of the company’s stock after selling 103 shares during the period. Johnson & Johnson comprises about 2.4% of Wedgewood Investors Inc. PA’s portfolio, making the stock its 7th biggest position. Wedgewood Investors Inc. PA’s holdings in Johnson & Johnson were worth $1,626,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Newfound Research LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $28,000. Islay Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $42,000. FAI Wealth Management lifted its stake in shares of Johnson & Johnson by 45.9% in the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares during the period. SeaBridge Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares during the period. Finally, Crewe Advisors LLC lifted its stake in shares of Johnson & Johnson by 909.1% in the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.
A number of research analysts have recently issued reports on the company. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Credit Suisse Group boosted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Cantor Fitzgerald upped their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus price target of $164.93.
Shares of Johnson & Johnson stock opened at $146.36 on Friday. The company has a market cap of $385.30 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The business has a 50 day moving average price of $145.51 and a 200-day moving average price of $146.57. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.12 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 7.99 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. The ex-dividend date of this dividend is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Why are trading ranges significant?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.